BioSpace News Archive

Consolidated operating income increased 43.5% (17% when normalized) to $2.0 million on 1% revenue growth

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.75 per common share, payable on September 28, 2018 to holders of record on September 7, 2018.

In Congressional testimony, Hazelden Betty Ford Foundation CEO Mark Mishek calls for quality standards, regulatory reforms and a national ban on “patient brokering”

California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, today applauded the U.S. House passage of H.R. 184, the Protect Medical Innovation Act, which permanently repeals the job and innovation hindering 2.3% medical device excise tax levied on medical technology companies.

25-Year Industry Veteran to Lead Company through Next Chapter of Growth

Eton Pharmaceuticals , Inc., a specialty pharmaceutical company, announced positive top-line results for its phase III study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation for the treatment of ocular itching associated with allergic conjunctivitis.

Study evaluated the utility of Banyan BTI™, a diagnostic blood test, to rule out the need for a CT scan in patients with a suspected mild TBI, or concussion, presenting to the emergency department within 12 hours of head injury.

Aquestive Therapeutics, Inc. announced the pricing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $67,500,000.

bluebird bio, Inc. announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.50 per share

Sponsored by State Representative Daniel Cahill, the legislation recognizes cancer as a work-related injury for firefighters, allowing them better access to treatment